Repatha linked to 20% lower all-cause mortality in VESALIUS-CV analysis at ESC

Amgen presented a pre-specified secondary analysis of the VESALIUS-CV trial at ESC Congress 2026 on August 31, 2026, showing a 20% reduction in all-cause mortality with Repatha. The analysis covers more than 12,000 high-risk adults without a prior heart attack or stroke who were on statins or other LDL-lowering therapy. The reduction in deaths appeared after about 1.5 years of treatment and held over a median follow-up of 4.6 years; the release gave no confidence interval or p-value.

• All-cause mortality reduced by 20%
• Pre-specified secondary analysis of VESALIUS-CV, more than 12,000 patients
• Median follow-up of about 4.6 years
• Published simultaneously in Circulation
• No confidence interval or p-value in the release